Philip Morris Secures FDA Modified-Risk Claim for 20 Zyn Pouches, Smoke-Free Revenues at 43%
PM•The U.S. FDA granted modified-risk authorization for 20 Zyn nicotine pouches, allowing Philip Morris to promote lower health risks. Smoke-free products contribute 43% of net revenues and operating cash flow reached $12.23B in 2025, with $13.5B forecast for 2026.
1. FDA Authorizes Modified-Risk Claims
The U.S. Food and Drug Administration approved modified-risk labeling for 20 Zyn nicotine pouch products, enabling Philip Morris to officially market them as lower-risk alternatives to traditional cigarettes.
2. Smoke-Free Products Drive Revenues
Heat-not-burn devices and nicotine pouches now represent 43% of net revenues, reflecting growing consumer adoption as traditional cigarette volumes decline.
3. Strong Cash Flow Outlook
Operating cash flow climbed to $12.23 billion in 2025 and is forecast to reach $13.5 billion in 2026, underpinning the company’s capacity to fund its dividend and reduce leverage.
4. Neutral Rating and Financial Concerns
UBS raised its price target to $182 but maintained a Neutral rating, citing negative shareholders’ equity of $7.3 billion and ongoing debt reduction efforts following the Swedish Match acquisition.
